Organisation paid for research Program year 2022 Source: CMS Open Payments

Massachusetts General Physician

Neither a doctor nor a teaching hospital

Research payments

$1,360,895

388 payments

Through program year 2022, Massachusetts General Physician is reported as receiving $1,360,895 in research payments, across 388 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$76,390	10
2021	Research	$144,230	100
2020	Research	$142,855	85
2019	Research	$997,420	193

Breakdown

Who paid Research payments · program years 2019–2022

AbbVie, Inc. $1,123,525 320 payments
UCB Biosciences Inc. $156,150 20 payments
Pharmacyclics LLC, An AbbVie Company $81,220 48 payments

Studies the money was for Research payments · program years 2019–2022

M13-694 $644,255 54 payments
M13-813 $142,360 22 payments
M16-283 $60,450 62 payments
A Multicenter, Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis $42,580 7 payments
M14-031 $42,195 5 payments
M13-813 $41,160 3 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis $38,625 3 payments
A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women with Osteoporosis $37,025 4 payments
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) $36,900 22 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference (Adalimumab) Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis $36,750 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.